News

A recent study reveals that treating gout effectively lowers cardiovascular risks, highlighting the importance of personalized urate-lowering therapy.

A recent trial reveals that transcutaneous auricular vagus nerve stimulation does not significantly reduce pain in erosive hand osteoarthritis compared to placebo.

Abatacept shows potential to delay rheumatoid arthritis progression for up to four years, but benefits diminish after treatment cessation.

Positive data from a phase 2 study were previously presented at the 2025 ACR Convergence.

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

This FDA News Month in Review provides a round-up of regulatory decisions from December 2025.

The rheumatoid arthritis year in review highlights FDA approvals, data, and advances in 2025.

The fibromyalgia year in review highlights FDA approvals, data, and advances in 2025.

New advances in fibromyalgia are part of a larger shift in pain management in 2025.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

Six weeks of freshly squeezed lemon juice diluted in water significantly reduced serum urate and improved kidney function in patients with gout and hyperuricemia.

Patients with gout frequently experience kinesiophobia and central sensitization, which were independently linked to greater pain intensity.

New research shows both left and bilateral taVNS are safe, noninvasive treatment options that relieve pain in individuals with fibromyalgia.

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

A large prospective cohort study showed that moderate dietary diversity, particularly greater intake of grains, dairy, vegetables, and fruits, is linked to reduced gout risk.

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.

Evidence shows fibromyalgia patients face higher overactive bladder rates and symptom severity, highlighting the importance of integrated care.

Multicenter study shows patients with both CKD and gout achieve better urate control on febuxostat than those with gout alone, despite the lower doses.

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

In a phase 3 trial, the first-in-class triple agonist delivered up to an average of 71.2 lbs weight loss and reduced WOMAC pain scores for knee osteoarthritis.